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Type 1 diabetes (T1D) is an autoimmune disease, in which pancreatic β cells are destroyed in genetically predisposed individuals.
While the direct contribution of autoantibodies to the disease pathogenesis is controversial, it is generally recognised that the
mechanism of β cell destruction is mediated by autoreactive T cells that had escaped the thymic selection. We aimed to design a
method to detect circulating CD8+ T cells autoreactive against an epitope of the glutamic acid decarboxylase autoantigen, isoform
65 (GAD65) ex vivo in T1D patients by using HLA class I tetramers. Low frequencies of GAD65 peptide-speciﬁc CD8+ cytotoxic T
lymphocytesweredetectedinperipheralbloodlymphocytes(PBMC)ofnormalcontrolsafterGAD65peptide-speciﬁcstimulation.
Conversely, theirfrequencies were signiﬁcantly higher than incontrolsin PBMCof T1Dpatients afterGAD65peptide stimulation.
These preliminary data are encouraging in order to develop a reliable assay to be employed in large-scale screening studies.
Copyright © 2009 Laura Giuliani et al. This is an open access article distributedunder theCreative CommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
T1D is a chronic autoimmune disease where CD4+ and
CD8+ T cells recognizing islet autoantigens are likely the
mediatorsofselectivedestructionofpancreaticisletbetacells
[1]. Although direct demonstration of the prominent role of
T cells in the disease progression is provided only in animal
models, the preclinical period of the disease in humans is
marked by the presence of circulating islet-related autoan-
tibodies to beta cell antigens including insulin, glutamic acid
decarboxylase (GAD), isoforms GAD65 and GAD67, the
insulinoma-associated antigen (IA2)/tyrosine phosphatase-
like molecule, IA-2 β or phogrin, and proinsulin [1].
From the 1990s onwards several laboratories produced
an increasing number of reports regarding the detection
of T cells directed against these antigens in the periph-
eral blood. The ﬁrst attempts employed [3H]thymidine
incorporation/proliferation assays setup with PBMC of
T1D patients (at onset or long-standing) and their “high-
risk” (ICA+) or “low-risk” (ICA-) ﬁrst degree relatives
[2]. Subsequently, ELISPOT assays were implemented for
measuring cell-mediated immune (CMI) responses in T1D
[3–5] and immunoblot assays [6]. Costimulatory anti-
CD28 antibodies were shown to enhance autoreactive T cell
responses to GAD65 peptides in T1D patients [7], while,
in a previous set of experiments, the expansion of the
GAD65 (whole molecule) reactive T cells was costimulation
dependent in healthy controls, as opposed to T1D patients
[8].
Nevertheless, T cell results were largely inconclusive
because autoantigen-speciﬁc T cells in an in vitro expan-
sion could indeed be grown both from patients and con-
trols, as evidenced by 4 International Workshops of the
“Immunology Diabetes Society” and by multicenter-blinded
control trials, organized under the auspices of the “Immune
Tolerance network” [9–11]. Several explanations were put2 Journal of Biomedicine and Biotechnology
forward for justifying these diﬃculties including [12] their
low precursor frequency, the inhability to identify them from
the vast excess of T cells, and their low to moderate aﬃnity
to self-antigens.
Cytotoxicity assays, set in vitro, oﬀered proofs that T
lymphocytes are potentially able to kill target cells also in
vivo. To this end HLA-A∗0201 restricted CD8+ cytotoxic T
lymphocytes, speciﬁc for a GAD65 decapeptide (114–123),
were ﬁrst detected in PBMC of recent onset T1D patients
and in “high-risk” (ICA+) individuals by using the classical
[51Cr] release cytotoxicity assay [13].
In more recent investigations ELISPOT assays revealed
IFN-γ production when PBMC from T1D patients were
challenged with proinsulin peptides (30–39; 34–42; 41–
50) [14] and the amyloid polypeptide precursor protein
(ppIAPP5–13) peptides [15]. The nonapeptides ppIAPP9–
17, IGRP152–160, and IGRP215–223 from the islet-speciﬁc
glucose-6-phosphatase catalytic subunit related protein and
nonapeptides 172–180 and 482–490 from the islet autoanti-
gen IA-2 [16] that would bind to and stabilize the HLA-A2
molecules were also identiﬁed.
MHC tetramer technology was initially introduced
to target antigen-speciﬁc CD4+ T cells in patients with
viral, bacterial infections [17], tumors [18]. In reference
to human autoimmunity class II tetramers successfully
detected GAD65 [19], proinsulin [20], IA-2, and pre-
proinsulin [21]r e a c t i v eC D 4 +Tc e l l si nP B M Co fT 1 D
patients, low percentages of CD4+ T cells autoreactive to
GAD65, the melanocyte diﬀerentiation antigen tyrosinase
and the testis tumor antigen NY-ESO-1 (epitope 120–
131) in PBMC of healthy individuals [22], and CD4+
gluten-speciﬁc T cells in PBMC of celiac disease patients
[23]. The HLA class I tetramer technology successfully
detected circulating CD8+ T lymphocytes autoreactive to
the melan A autoantigen in patients with vitiligo [24],
the PBC-E2 autoantigen in patients with primary biliary
cirrhosis (PBC) [25], vimentin in patients who were heart
transplanted [26], and insulin beta chain nonapeptide
(InsB10-18) [27]. In a recent investigation HLA-A∗0201
GAD65 (114–122) pentamers detected an increased per-
c e n t a g eo fa u t o r e a c t i v eTc e l l si nt h eC D 4 5 R O +s u b s e t
in T1D patients as compared with controls [28]. In long-
standing T1D patients who, after islet transplantation, have
a loss of islet allograft and recurrent autoimmunity a high
frequency of GAD65-speciﬁc T cell clones was found within
the expanded autoreactive memory T cell compartment
[29].
In the light of all the aforegoing, we attempted in this
preliminary study to device a more sensitive methodology
than those currently available for measuring CMI responses
and, in particular, GAD65 autoreactive T cells in T1D.
Preliminary data indicate that it is possible to implement
an assay that still will require appropriate standardization
before being used in large scale screening programs. In our
protocol, after stimulation of the cells with the GAD65 114-
122 epitope, we successfully detected a percentage of CD8+
GAD autoreactive T cells in a sample population including
15 T1D patients (9 newly diagnosed and 6 long-standing) by
using HLA class I tetramers.
2.MaterialsandMethods
2.1. Patients and Controls. 9H L A - A ∗0201 positive pediatric
patients (4 males and 5 females, age of onset range 9.2
years to 16.4 years, mean 12.8 years) were recruited from
Lazio region at the onset of T1D at the Unit of Pediatric
Endocrine Autoimmune Diseases at the Children’s Hospital
Bambino Ges` u, Rome (Table 1). We also included 6 long-
term HLA-A∗0201 positive pediatric T1D patients (between
8 months to 4 years and 5 months after diagnosis). The
control population was recruited at the Blood Transfusion
Center of our Hospital including 10 HLA-A∗0201 positive
nondiabetic healthy blood donors. They had no history
of autoimmunity and no islet-related autoantibodies were
detected in their serum.
2.2. PBMC Isolation. After obtaining informed consent from
parents of childrens and normal controls, PBMC were
separated by Ficoll-Hypaque (Histopaque, Sigma-Aldrich
Chemical C, St Louis, MO, USA) from 5–10mL sodium-
heparinized venousblood samples,washedtwiceinPBS,and
then frozen down in liquid nitrogen.
2.3. HLA-A2 Typing and Subtyping. HLA-A2 typing was
initially performed by Flow cytometry analysis and sub-
sequently conﬁrmed by standard allele-speciﬁc PCR. In
the initial screening, 1 × 106 c e l l sw e r ei n c u b a t e d ,f o r3 0
minutes in ice, with an anti-HLA-A2 mouse mAb (1 :
10 dilution, One Lambda, Inc, Canoga Park, CA, USA).
After washing by centrifugation at 1500rpm for 5 minutes
at room temperature (RT) in wash buﬀer [0,1% sodium
azide, 2% fetal bovine serum (FBS, Hyclone, South Logan,
UT, USA) in PBS], cells were resuspended in the residual
volume (approximately 50μL). 1μL of ﬂuorescent- (FITC-)
conjugated goat anti-mouse IgG (Fc γ fragment speciﬁc
antibody) (Jackson ImmunoResearch Laboratories Inc, West
Grove, PA, USA) was added. Cells were then incubated in
ice for 30 minutes in the dark, washed in wash buﬀer,
and acquired for the analysis in a Becton & Dickinson
FACSCalibur ﬂow cytometer equipped with the Cell Quest
software program.
HLA-A2 subtyping was carried out using a molecular
system (GenoVision Inc., West Chester, PA, USA); high-
resolution DNA-based HLA typing of polymorphic class I
loci HLA-A, -B, and -C was also carried out according to a
reverse line blot system [30].
2.4. Isolation and Stimulation of PBMC with the GAD65
Peptide. At the time of tetramer assay, cells were thawed
and resuspended, at a density of 1 × 106/mL, in RPMI-
1640 (GIBCO/BRL, Invitrogen, Gaithersburg, CA, USA),
supplemented with 2mmol/L L-glutamine, 100μg/mL peni-
cillin/streptomycin, and 10% v/v FBS; cells were then
cultured in the presence of the GAD65 peptide AA 114–122
(VMNILLQYV) at a concentration of 30μg/mL, for 4 days
in 24-well round-bottomed plates (Falcon, Labware BD Bio-
sciences, Oxnard, CA, USA) (1 ×106 cells/well). The GAD65
nonapeptide had been selected for its high aﬃnity bindingJournal of Biomedicine and Biotechnology 3
Table 1: Sex, age, islet-related autoantibody (IA-2A, IAA and GADA) proﬁle, and associated disorders in 9 newly diagnosed T1D patients at
disease onset. The diagnosis of T1D was done according to the WHO and the American Diabetes association (ADA) criteria. NT: not tested;
pos: positive; neg: negative.
T1D
patient Sex Age at onset
(years)
IA-2A
(cut-oﬀ <1.1)
IAA
(cut-oﬀ<7%)
GADA∗
(cut-oﬀ <3) Associated disorders
1 F 10.9 neg (0.1) neg (4) pos (63) desquamative dermatitis
2 M 10.0 pos (28) neg (4) pos (8.6) none
3 F 14.7 pos (20) pos (8) pos (13) anti-thyroid antibodies positive, mild
obesity
4 F 12.6 pos (7.9) neg (4.7) pos (19) hypercolesterolemia
5 M 9.2 pos (3.6) pos (56) neg (0.1) none
6 M 16.4 pos (8) neg (4.7) neg (2.5) autoimmune thyroiditis, LT4 replacement
therapy
7 M 11.8 neg (0.4) pos (74) pos (5.5) none
8 F 8.4 pos (1.3) pos (11) pos (1) none
9 F 9.4 pos (44) pos (16) pos (7) anti-thyroid antibodies positive
∗Assay performed at San Raﬀaele Hospital, Milan, Italy. GADA and IA-2A measurements were performed by radiobinding assay with in vitro translated 35S-
methionine-labeled GAD65 or IA-2 [31, 32]. IAA were measured using a competitive protein A/G insulin radiobinding assay [33].
to HLA A∗0201 in an HLA peptide motif search Database
(http://www-bimas.cit.nih.gov/molbio/hla bind). In parallel
experiments control cell cultures were set up by incubating
PBMC from the same individual with IL-2 (25IU/mL,
Sigma) for 4 days, in place of the GAD65 peptide, in order
to ensure that PBMC would live for the entire culture period
priortotheﬂowcytometryanalysis(videinfra).Attheendof
the4 days, PBMC, eitherstimulated withthe GAD65 peptide
or incubated with IL-2, were washed in calcium-magnesium
free Dulbecco’s phosphate-buﬀered saline 1X (Euroclone,
Wethersby, West York, UK), by centrifugation at 1500rpm
for 5 minutes at RT. This washing was introduced to remove
the excess of GAD65 peptide and IL-2 from the culture, so
to maximally reduce the risk of nonspeciﬁc binding, when
PBMC will subsequently be stained with labeled tetramers.
The two sets of PBMC were cultured for additional two days
with IL-2 (25IU/mL) in the same medium (RPMI-1640,
2mmol/l L-glutamine, 100μg/mL penicillin/streptomycin,
10% v/v FBS).
2.5. HLA-A∗0201 Peptide-Tetramers. Phycoerythrin (PE)
labeled tetramers were generated, using either the GAD65
peptide (VMNILLQYV) or the Flu peptide (GILGFVFTL)
[34], known to have a high-aﬃnity binding with HLA-
A∗0201(purchasedfromProImmuneLimited,Oxford,UK).
2.6. Cell Staining with HLA A∗0201/GAD65 Peptide
Tetrameric Complexes. On day 6, approximately 5 × 105
cells, stimulated with the GAD65 peptide or cultured with
IL-2, were allocated for staining conditions. Cells were
washed by centrifugation at 1500rpm for 5 minutes at
RT in wash buﬀer (0.1% sodium azide, 2% FBS in PBS)
and resuspended in the residual volume (approximately
50μL). 1μL of phycoerithrin (PE) labeled GAD65 peptide
(VMNILLQYV) tetramer was added to each cell preparation
and incubated in ice for 30 minutes in the dark, then washed
in wash buﬀer. 1μL of mAb anti-human CD8 (FITC labelled
(Becton & Dickinson, Pharmingen, San Diego, CA, USA))
and 5μL of mAb anti-human CD3 [allophycocyanin (APC)
labelled (Becton & Dickinson)] were added for further
staining the diﬀerent cell preparations. In alternative for
CD8 staining, 1μL of biotinylated mAb anti-human CD8
(1 : 10, Becton Dickinson) was used followed by streptavidin
cychrome (Cys5) conjugate (1 : 10, Southern Biotechnology,
Birmingham, AL, USA). Cells were incubated in ice for at
least 30 minutes in the dark, washed twice in wash buﬀer,
and then immediately acquired for the analysis in a Beckton
& Dickinson FACSCalibur ﬂow cytometer and CellQuest
software program.
2.7. Tetramer Assay Controls
2.7.1. Sensitivity of the Tetramer Assay. In order to verify the
sensitivity of the HLA-A∗0201 tetramer assay, the Flu non-
apeptide (GILGFVFTL) was used to stimulate PBMC of one
HLA-A∗0201 normal individual. This test was performed in
ordertoverifythatwecouldobtainanincreasedsensitivityof
the Flu tetramer staining after Flu peptide stimulation. The
stainingwiththeFlutetramerwascarriedouteitherbydirect
assayexvivoorafterstimulationofthesamePBMCﬁrstwith
theFlupeptide(3.5μg/mL)for4daysfollowed,afterwashing
the cells, by an incubation with IL-2 for 2 days.
2.7.2. Positive Stimulation Controls. A positive control of
stimulation was introduced in all the experiments in order
to prove that in vitro stimulation worked in all subjects,
including those from whom no GAD speciﬁc T cells were
detected. The presence of Flu tetramer positive cells was
assessed in randomly selected samples by staining after Flu
peptide stimulation.
2.7.3. Speciﬁcity of the Tetramer Binding. In order to verify
the speciﬁcity of the reactivity of the GAD65 HLA A∗0201
tetramer in the detection of GAD65 nonapeptide reactive
T cells and as control of nonspeciﬁc binding, PBMC of4 Journal of Biomedicine and Biotechnology
randomly selected T1D patients and controls were cultured
separately with the GAD65 nonapeptide, the Flu nonapep-
tide, and IL-2. The Flu and GAD65 nonapeptides were
used at the same concentration (10–30μg/mL). After 4 days,
PBMC, cultured in the 3 diﬀerent conditions, were washed
andsubsequentlyincubatedwithIL-2aloneforanadditional
2 days. Cells were then recovered, washed, and stained
with the GAD65 nonapeptide HLA A∗0201 tetramers and
analyzed by ﬂow cytometry.
2.8. Statistical Analysis and Cutoﬀ Extimation. Diﬀerences
in the percentages of CD3+/CD8+/GAD65 reactive T cells
between normal controls and T1D patients in each (IL-2
and GAD65 peptide) stimulated PBMC populations were
assessedbyMann-Whitney-Utest.Variationsintheresponse
of PBMC, either treated with IL-2 or stimulated with the
GAD65 peptide within each group (i.e., controls versus T1D
patients), were evaluated by Wilcoxon’s test. A P value less
than .05 was considered as signiﬁcant.
3. Results
3.1. Selection of HLA-A∗0201 Restricted High-Aﬃnity Binder
GAD65 Epitope. It is well known that HLA class I molecules
bind peptides 8–10 aminoacids long, but preferentially
nonapeptides [35, 36]. After database search for nonamers
of the GAD65 protein sequence (P48320, NCBI Database),
we selected peptide GAD65 114-122, on the basis of its high
score of aﬃnity binding (1080.239) to HLA-A∗0201.
3.2. GAD65-Speciﬁc CD8+ T Cells in PBMC of Normal
controls and T1D patients are Identiﬁed by HLA Class I
Tetramer Staining
3.2.1. Detection of Flu Reactive T Cells in Normal Controls.
Direct staining ex vivo with HLA A∗0201 Flu peptide
tetramers of PBMC of a normal HLA A∗0201 positive
individual detected 0.03% of CD3+/CD8+/Flu reactive T
cells. The percentage increased to 0.23%, when PBMC of the
sameindividualwereﬁrststimulatedfor4dayswiththesame
Flu peptide (data not shown).
3.2.2. Detection of GAD65 Peptide Reactive T Cells
Normal Controls. In PBMC of normal individuals no
signiﬁcant variations were found in the percentage of
CD3+/CD8+/GAD65 reactive T cells between PBMC cul-
tured with either IL-2 or the GAD65 peptide (Mann-
Withney test versus PBMC IL-2 treated P = .05, Figure 1).
TD Patients. In PBMC of T1D patients the percentage of
CD3+/CD8+/GAD65 reactive T cells were signiﬁcantly more
pronounced in comparison to those registered with PBMC
of controls after stimulation with the same GAD65 peptide
(P = .001 T1D versus controls, Figures 1 and 2).
Figure 2 shows PBMC of a representative T1D patient
treated with IL-2 (panel (a), (b), (c)) and with GAD65
peptide (panel (d), (e), (f)). The analysis was conducted
P = .001§
P = .03∗
P = .07§
P = .05∗
∗Mann-Whitney rank-sum test
§ Wilcoxon signed-rank test
GAD IL-2 GAD IL-2
T1D patients Healthy controls
0
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Figure 1: Statistical analysis of the percentages of CD3+/CD8+/
GAD65 peptide autoreactive T cells in PBMC of normal controls
(n = 10) and T1D patients (n = 15). In PBMC of T1D
patients, cultured with IL-2 alone for 4 + 2 days, the median
of CD3+/CD8+/GAD65 reactive T cells was 0.70 [interquartile
range (0.22–1.19); range (0.00–4.3)], while when cultured with
the GAD65 peptide for 4 days and IL-2 for additional 2 days,
the median was 0.81 [interquartile range (0.50–4.04); range (0.14–
15.6)] (Mann-Whitney U Test PBMC GAD65 peptide stimulated
versus PBMC IL-2 treated, P = .03; Wilcoxon’s Test PBMC of T1D
patients versus PBMC of controls, both cultured with IL-2, P = .07;
Wilcoxon’s Test PBMC of T1D patients versus PBMC of controls,
both stimulated with GAD65 peptide, P = .001).
only in R1 region (living cells as evidenced by morphological
parameters) and in the R2 region (CD3+/CD8+ cells). The
population of CD3+/CD8+/GAD65 reactive cells was shown
in panel (f) (4.04% of total cell population).
IL-2 treatment aﬀected diﬀerentially the detection of
CD3+/CD8+/GAD65 reactive T cells in T1D patients versus
control (P = .07 T1D patients versus controls) (Figure 1).
Speciﬁcity of the GAD65 Peptide Response. The percentage of
CD3+/CD8+/GAD65 reactive T cells estimated in PBMC of
single patients after GAD65 peptide stimulation was higher
thanafterFlupeptidestimulationorwhenculturedwithIL-2
alone (data not shown). With PBMC of the normal controls,
the percentage of CD3+/CD8+/GAD65 reactive T cells was
comparable in the 3 stimulation conditions. In principle,
we assume that the speciﬁc reactivity could be detectable
in each single sample only after GAD65 peptide stimula-
tion. This test is an alternative to control the nonspeciﬁc
binding of tetramer to T cells with the use of an irrelevant
peptide.
4. Discussion
Tetramers containing autoantigenic peptides have clinical
utility in autoimmunity for diagnostic and, potentially,
therapeutic applications [19–29]. Previous studies [19, 20]Journal of Biomedicine and Biotechnology 5
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Figure 2: Density plots of cytometric analysis of PBMC of one representative T1D patient at day 6 of culture. (a), (b), (c) Cells stimulated
with IL-2; (d), (e), (f) cells stimulated with the GAD65 peptide. (a), (d) Density Plots of morphological parameters (FSC-H; SSC-H) of
cells treated with IL-2 and GAD65, respectively. In gate R1 cells were selected by morphological parameters as living cells. In the subsequent
panels ((b), (c), (e), (f)) only this region was considered. ((b), (e)) Density Plots of CD3 APC and CD8 FITC cells, treated with IL-2 and
GAD65 peptide, respectively. Positive CD3/CD8 cells were selected in R2 gate. In (c) and (f) panel only R2 gate was considered and the
percentage in the upper right quadrant represented CD3+/CD8+/GAD65 reactive T lymphocytes.
clearly demonstrated that MHC class II tetramers can
eﬃciently detect GAD65 reactive CD4+ T cells in PBMC
of T1D patients. GAD65-speciﬁc HLA DR0401-restricted
clones could be even derived from a diabetic patient using
tetramers as stimulating agent. GAD65 tetramers could also
deliver activation signals in the generated clones [33].
These encouraging data prompted us to trace GAD65
autoreactive T cells in T1D; in the present investigation
HLA-A∗0201 tetramers were therefore constructed with a
“natural” peptide (GAD65 (AA114–122), half-time disasso-
ciation 1080,239). This peptide has been used in previous
class I tetramer investigations [28, 29] and now employed to
establish a more sensitive assay. We could have chosen the
GAD65 decamer (AA114–123) [13] but the peptide ranked
low in the aﬃnity binding scale (half time disassociation,
35.012). In addition, the terminal valine in position 122
seems to be relevant for the antigenic presentation of the
motif, as the very low-aﬃnity binding of the nonapeptide
115–123 to HLA A∗0201 (half time disassociation, 0.316)
demonstrates. We argue against the use of “modiﬁed”
peptides for assembling tetramers [24] employed in previous
investigationsinordertoincreasetheiraﬃnitybindingtothe
tetramer.
There have been two ways of performing HLA class
I tetramer assays. The ﬁrst is by direct ex vivo staining
with labeled peptide/tetramer complexes [24]; in the second
method PBMC are preincubated and stimulated with the
peptide and then stained with the labeled peptide/tetramer
or pentamer complexes [25–29]. We have chosen the second
approach, because we believe that preincubation with the
peptide might induce a limited speciﬁc T cell expansion in
vitro and, therefore, may increase the chance to “awake”
autoreactive CD8+ T cells.
Novel steps in the experimental procedure were designed
as follows: (1) a reduced period of antigen-speciﬁc cell
expansion (4 days rather than 21 days [27], 28 days [26],
10 days [28], time course selected in other HLA class I
tetramer assays); (2) an intermediate washing step after
cells were stimulated with the GAD65 nonapeptide; (3) a
2-day incubation with IL-2 in the absence of the GAD65
nonapeptide; and (4) a ﬁnal washing step, before staining the
cellswiththelabeledtetramers.Inaddition,wereliedonlyon
the autologous APCs, present in the pool of the PBMC, not6 Journal of Biomedicine and Biotechnology
prepulsed with the nonapeptide, as it was done in previous
assays [27], and we set up parallel PBMC cultures either
with IL-2 alone, an internal cell culture control. The short
period of peptide stimulation has the advantage that cultures
are terminated before clonal expansion and/or “in vitro”
cell diﬀerentiation can occur. We need also to underline
that the possibility of testing frozen/defrosted PBMC is of
paramount importance when planning large retrospective
epidemiological investigations.
By applying these novel experimental conditions, the
recovery of CD3+/CD8+/GAD65 reactive T cells in T1D
patients ranged from 0.5% to 15.6% after GAD65 peptide
stimulation of PBMC. To our knowledge, this is the highest
percentage of autoreactive CD8+ Tc e l l se v e r“ c a p t u r e d ”b y
HLA class I tetramers in PBMC of patients with a human
autoimmune disease (0,1% to 1% in vitiligo [24]4 , 2 %i n
heart transplantation [26]; up to 0.4% of CD8+ CD45RO+
T cells in newly diagnosed T1D patients [28]; between 2.6%
and 8.3% within the Ki-67+CD8+ cell fraction (1.65% + / −
0.25% of the total CD8+ lymphocytes) in islet transplanted
T1D patients [29]).
5. Conclusions
Wesetupafeasibleassaythatwillnowrequireanappropriate
standardisation. This can be achieved by testing PBMC
of a large number of T1D patients, normal controls, and
especiallyprediabetic high-risk individuals. A valid statistical
evaluation of results will help to establish an appropriate
cutoﬀ value of positivity in the assay.
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